Table 6.
Risk of Stroke at 3 Months for Clopidogrel–Aspirin Combined Therapy Comparing With Aspirin Alone by METS (Chinese Diabetes Society) Status
| METS Status | Aspirin | Clopidogrel–Aspirin | Model 1a | Model 2b | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Events, n (%) | n | Events, n (%) | Adjusted HR (95% CI) | P Value | P Value for Interaction | Adjusted HR (95% CI) | P Value | P Value for Interaction | |
| Neither | 793 | 63 (7.9) | 825 | 47 (5.7) | 0.71 (0.49–1.04) | 0.08 | 0.87 | 0.70 (0.48–1.02) | 0.07 | 0.82 |
| METS only | 278 | 28 (10.1) | 247 | 13 (5.3) | 0.52 (0.27–1.00) | 0.050 | 0.48 (0.24–0.93) | 0.03 | ||
| DM only | 302 | 59 (19.5) | 300 | 38 (12.7) | 0.63 (0.42–0.94) | 0.03 | 0.60 (0.40–0.90) | 0.01 | ||
| Both | 153 | 31 (20.3) | 146 | 20 (13.7) | 0.67 (0.38–1.18) | 0.16 | 0.71 (0.40–1.27) | 0.25 | ||
DM indicates diabetes mellitus; HR, hazard ratio; METS, metabolic syndrome.
a
Model 1: adjusted for age and sex.
b
Model 2: adjusted for age, sex, history of ischemic stroke, transient ischemic attack, myocardial infarction, angina, congestive heart failure, known atrial fibrillation or flutter, valvular heart disease, smoking status, index event and National Institutes of Health Stroke Scale on admission, and time to randomization.